Announcements Trials
Browse Landscape

Phase

Phase 1 10Phase 2 4Phase 1/2 2Phase NA 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 10Lymphoma, Follicular 10Lymphoma 8Lymphoma, Large B-Cell, Diffuse 7Leukemia, Lymphocytic, Chronic, B-Cell 7Recurrence 5Lymphoma, Mantle-Cell 5Neoplasms 3Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Hairy Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Burkitt Lymphoma 1Anemia 1

Interventions

Cyclophosphamide 25Rituximab 22fludarabine 14Lenalidomide 10Vincristine 8Doxorubicin 8Prednisone 7Etoposide 7fludarabine phosphate 6Immunotherapy, Adoptive 5polatuzumab vedotin 4Cytarabine 4CT-P10 4Bendamustine Hydrochloride 4Antigens, CD19 4tocilizumab 3Gemcitabine 3Dexamethasone 3Carboplatin 3venetoclax 2veltuzumab 2prednylidene 2ofatumumab 2obinutuzumab 2ixazomib 2ibrutinib 2etoposide phosphate 2deltacortene 2carmustine, poliferprosan 20 drug combination 2acalabrutinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, B-Cell × obinutuzumab × Clear all
NCT06634589 2026-06-03

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

BeOne Medicines

Phase 1/2 Recruiting
80 enrolled
Lymphoid

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT07520006 2026-04-13

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Nurix Therapeutics, Inc.

Phase 1/2 Not yet recruiting
150 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡